Search

Your search keyword '"Falchook, Gerald S."' showing total 16 results
Start Over Author "Falchook, Gerald S." Publisher american association for cancer research
16 results on '"Falchook, Gerald S."'

1. Abstract CT189: Improved progression-free and overall survival (PFS/OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial

Author

Yap, Timothy Anthony, primary, Gainor, Justin F., additional, Callahan, Margaret K., additional, Falchook, Gerald S., additional, Pachynski, Russell Kent, additional, LoRusso, Patricia, additional, Kummar, Shivaani, additional, Gibney, Geoffrey Thomas, additional, Burris, Howard A., additional, Tykodi, Scott S., additional, Rahma, Osama E., additional, Seiwert, Tanguy, additional, Papadopoulos, Kyriakos P., additional, Hooper, Ellen, additional, Harvey, Christopher J., additional, Hanson, Amanda, additional, Lacey, Sean, additional, McComb, Rachel, additional, Hart, Courtney, additional, Laken, Haley, additional, McClure, Ty, additional, and Trehu, Elizabeth, additional

Published
2019
Full Text
View/download PDF

4. Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation

Author

Hamilton, Erika, primary, Falchook, Gerald S., additional, Wang, Judy S., additional, Fu, Siqing, additional, Oza, Amit, additional, Karen, So, additional, Imedio, Esteban Rodrigo, additional, Kumar, Sanjeev, additional, Ottesen, Lone, additional, Mugundu, Ganesh M., additional, Chmielecki, Juliann, additional, Jones, Suzanne, additional, Spigel, David R., additional, and Li, Bob T., additional

Published
2019
Full Text
View/download PDF

5. Abstract PR08: Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1

Author

Naing, Aung, primary, Infante, Jeffrey R., additional, Papadopoulos, Kyriakos P., additional, Wong, Deborah J., additional, Autio, Karen A., additional, Falchook, Gerald S., additional, Patel, Manish, additional, Pant, Shubham, additional, Patnaik, Amita, additional, Whiteside, Melinda, additional, Bendell, Johanna C., additional, Mumm, John, additional, Chan, Ivan H., additional, Brown, Gail L., additional, VanVlasselaer, Peter, additional, Hecht, J. R., additional, Hong, David S., additional, Tannir, Nizar M., additional, and Oft, Martin, additional

Published
2016
Full Text
View/download PDF

6. Abstract CT098: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors

Author

Infante, Jeffrey R., primary, Naing, Aung, additional, Papadopoulos, Kyriakos P., additional, Autio, Karen A., additional, Ott, Patrick A., additional, Wong, Deborah J., additional, Falchook, Gerald S., additional, Patel, Manish, additional, Pant, Shubham, additional, Whiteside, Melinda, additional, Mumm, John B., additional, Chan, Ivan H., additional, Bendell, Johanna C., additional, Bauer, Todd M., additional, Janku, Filip, additional, Javle, Milind, additional, Colen, Rivka R., additional, Tannir, Nizar M., additional, and Oft, Martin, additional

Published
2016
Full Text
View/download PDF

7. Abstract 2413: Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform

Author

Janku, Filip, primary, Huang, Helen J., additional, Claes, Bart, additional, Falchook, Gerald S., additional, Fu, Siqing, additional, Tsimberidou, Apostolia M., additional, Hong, David S., additional, Naing, Aung, additional, Wheler, Jennifer J., additional, Piha-Paul, Sarina A., additional, Karp, Daniel D., additional, Subbiah, Vivek, additional, Zinner, Ralph G., additional, Ramzanali, Nishma, additional, Luthra, Rajyalakshmi, additional, Patel, Sapna P., additional, Kopetz, E. Scott, additional, Sablon, Erwin, additional, Maertens, Geert, additional, Kurzrock, Razelle, additional, and Meric-Bernstam, Funda, additional

Published
2015
Full Text
View/download PDF

8. Abstract 246: Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers

Author

Sakamuri, Divya, primary, Betancourt Cuellar, Sonia L., additional, Glitza, Isabella C., additional, Fu, Siqing, additional, Wheler, Jennifer J., additional, Falchook, Gerald S., additional, Tsimberidou, Apostolia M., additional, Hong, David S., additional, Subbiah, Vivek, additional, Fanale, Michelle A., additional, Cabanillas, Maria E., additional, Meric-Bernstam, Funda, additional, and Janku, Filip, additional

Published
2015
Full Text
View/download PDF

9. Abstract 2827: Association between new onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor (TKI) therapy in phase I clinical trials

Author

Bilen, Mehmet Asim, primary, Patel, Amy, additional, Hess, Kenneth R., additional, Munoz, Javier, additional, Busaidy, Naifa, additional, Abdelrahim, Maen, additional, Wheler, Jennifer, additional, Janku, Filip, additional, Falchook, Gerald S., additional, Hong, David S., additional, Meric-Bernstam, Funda, additional, Habra, Mohammed A., additional, and Naing, Aung, additional

Published
2014
Full Text
View/download PDF

10. Abstract C203:BRAFandKRASmutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers.

Author

Janku, Filip, primary, Legendre, Ben, additional, Richardson, Katherine, additional, Falchook, Gerald S., additional, Naing, Aung, additional, Holley, Veronica R., additional, Hong, David S., additional, Zinner, Ralph G., additional, Fu, Siqing, additional, Tsimberidou, Apostolia M., additional, Subbiah, Vivek, additional, Karp, Daniel D., additional, Piha-Paul, Sarina A., additional, Wheler, Jennifer J., additional, Stepanek, Vanda M., additional, Cabrilo, Goran, additional, Luthra, Rajyalakshmi, additional, Meric-Bernstam, Funda, additional, Kruempel, Amy, additional, Pope, Jaclyn, additional, Cubrich, Courtney, additional, Wu, Grant, additional, Shi, Yanggu, additional, Lewis, Marcia, additional, and Kurzrock, Razelle, additional

Published
2013
Full Text
View/download PDF

11. Abstract 1751: A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers

Author

Subbiah, Ishwaria M., primary, Kurzrock, Razelle, additional, Naing, Aung, additional, Piha-Paul, Sarina, additional, Falchook, Gerald S., additional, Hong, David S., additional, Wheler, Jennifer J., additional, Fu, Siqing, additional, Laday, Shell, additional, and Tsimberidou, Apostolia M., additional

Published
2012
Full Text
View/download PDF

12. Abstract LB-446: Target-based therapeutic matching in patients withPIK3CAmutations and PTEN aberrations

Author

Janku, Filip, primary, Wheler, Jennifer J., additional, Piha-Paul, Sarina A., additional, Stepanek, Vanda M., additional, Fu, Siqing, additional, Hong, David S., additional, Naing, Aung, additional, Falchook, Gerald S., additional, Moulder, Stacy L., additional, Luthra, Rajyalakshmi, additional, Tsimberidou, Apostolia M., additional, and Kurzrock, Razelle, additional

Published
2012
Full Text
View/download PDF

13. Abstract 1287: Profile-related evidence to determine individualized cancer therapy (PREDICT): Preliminary results of the Personalized Phase I Clinical Trials program at MD Anderson Cancer Center

Author

Tsimberidou, Apostolia Maria, primary, Hong, David S., additional, Wheler, Jennifer J., additional, Fu, Siqing, additional, Piha-Paul, Sarina, additional, Naing, Aung, additional, Falchook, Gerald S., additional, Luthra, Raja, additional, Iskander, Nancy G., additional, Wen, Sijin, additional, and Kurzrock, Razelle, additional

Published
2011
Full Text
View/download PDF

15. PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials.

Author

Janku, Filip, Wheler, Jennifer J., Aung Naing, Falchook, Gerald S., Hong, David S., Stepanek, Vanda M., Siqing Fu, Piha-Paul, Sarina A., Lee, J. Jack, Luthra, Rajyalakshmi, Tsimberidou, Apostolia M., and Kurzrock, Razelle

Subjects
*GENETIC mutation, *CLINICAL trials, *CANCER treatment, *COMBINATION drug therapy, *CANCER chemotherapy
Abstract

PIK3CA mutations may predict response to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype has not been investigated. Patients with diverse cancers referred to the Clinical Center for Targeted Therapy were analyzed for PIK3CA and, if possible, KRAS mutations. Patients with PIK3CA mutations were treated, whenever possible, with agents targeting the PI3K/AKT/mTOR pathway. Overall, 105 (10%) of 1,012 patients tested harbored PIK3CA mutations. Sixty-six (median 3 prior therapies) of the 105 PIK3CA-mutant patients, including 16 individuals (of 55 PIK3CA-mutant patients tested) with simultaneous KRAS mutations, were treated on a protocol that included a PI3K/AKT/mTOR pathway inhibitor; 17% (11/66) achieved a partial response (PR). Patients with a PIK3CA H1047R mutation compared with patients who had other PIK3CA mutations or patients with wild-type PIK3CA treated on the same protocols had a higher PR rate (6/16, 38% vs. 5/50; 10% vs. 23/174, 13%, respectively; all P ≤ 0.02). None of the 16 patients with coexisting PIK3CA and KRAS mutations in codon 12 or 13 attained a PR (0/16, 0%). Patients treated with combination therapy versus single-agent therapies had a higher PR rate (11/38, 29% vs. 0/28, 0%; P = 0.002). Multivariate analysis showed that H1047R was the only independent factor predicting response [OR 6.6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

16. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

Author

Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, and Kurzrock R

Subjects
Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms drug therapy, Neoplasms pathology, Precision Medicine, Prognosis, Prospective Studies, Signal Transduction, Survival Rate, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Gene Expression Profiling, High-Throughput Nucleotide Sequencing methods, Molecular Targeted Therapy, Neoplasms genetics
Abstract

Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve a major challenge for early-phase clinical trials, which is to recruit patients who, while having failed previous treatments, may nevertheless respond to molecularly targeted drugs. We report the findings of a prospective, single-center study conducted in patients with diverse refractory cancers who underwent comprehensive genomic profiling (CGP; next-generation sequencing, 236 genes). Of the 500 patients enrolled, 188 (37.6%) received either matched (N = 122/188, 65%) or unmatched therapy (N = 66/188, 35%). The most common reasons that patients were not evaluable for treatment included insufficient tissue, death, or hospice transfer. The median number of molecular alterations per patient was five (range, 1-14); median number of prior therapies, four. The most common diagnoses were ovarian cancer (18%), breast cancer (16%), sarcoma (13%), and renal cancer (7%). Of the 339 successfully profiled patients, 317 (93.5%) had at least one potentially actionable alteration. By calculating matching scores, based on the number of drug matches and genomic aberrations per patient, we found that high scores were independently associated with a greater frequency of stable disease ≥6 months/partial/complete remission [22% (high scores) vs. 9% (low scores), P = 0.024], longer time-to-treatment failure [hazard ratio (HR) = 0.52; 95% confidence interval (CI) = 0.36-0.74; P = 0.0003], and survival (HR = 0.65; 95% CI = 0.43-1.0; P = 0.05). Collectively, this study offers a clinical proof of concept for the utility of CGP in assigning therapy to patients with refractory malignancies, especially in those patients with multiple genomic aberrations for whom combination therapies could be implemented. Cancer Res; 76(13); 3690-701. ©2016 AACR., (©2016 American Association for Cancer Research.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results